Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03374488
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer Francois Baclesse, Caen, France
🇫🇷Clinique Victor Hugo, Le Mans, France
🇫🇷Centre Leon Berard, Lyon, France
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 93
- Registration Number
- NCT03361865
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Tennessee Medical Center Knoxville, Knoxville, Tennessee, United States
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT03361228
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 89
- Registration Number
- NCT03358472
- Locations
- 🇺🇸
U of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺Royal Brisbane & Women s Hospital, Herston, Queensland, Australia
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03348904
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 11
- Registration Number
- NCT03347123
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03342352
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 233
- Registration Number
- NCT03322566
- Locations
- 🇦🇺
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸St. Vincent Healthcare Frontier Cancer Center, Billings, Montana, United States
🇭🇺Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT03322540
- Locations
- 🇺🇸
Anne Arundel Health System Research Institute, Annapolis, Maryland, United States
🇺🇸Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03320642
- Locations
- 🇮🇹
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo, Pavia, Italy
🇫🇷Chru de Lille Hopital Claude Huriez, Lille, France
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States